Patients
NMOSD
From September 22, 2020, to December 24, 2021, a total of 17 patients were screened, and 14 patients were apheresed. CT103A was successfully manufactured in 13 patients; 1 was not dosed for personal reason (Fig. CONSORT diagram. *One patient suffered a severe NMOSD attack while her manufacturing failed. She refused another apheresis and discontinued before lymphodepletion. Demographic and clinical characteristics of the patients at baselineScores on the Expanded Disability Status Scale (EDSS) range from 0 (normal neurologic examination) to 10 (death)Attack frequency before, during, and after CAR T therapy